GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced that executives from the Company will be presenting at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time).
A live webcast of the presentation will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following the conference, an archived recording will be available on the Company’s website for at least 30 days.
About GoodRx
GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $45 billion and are one of the most downloaded medical apps over the past decade.
| Last Trade: | US$4.75 |
| Daily Change: | -0.08 -1.66 |
| Daily Volume: | 1,114,088 |
| Market Cap: | US$476.420M |
May 07, 2025 February 27, 2025 January 22, 2025 December 16, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
